Please use this identifier to cite or link to this item:
Title: On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Author: Lindsay, Colin R.
Garassino, Marina C.
Nadal, Ernest
Öhrling, Katarina
Scheffler, Matthias
Mazières, Julien
Keywords: Càncer de pulmó
Lung cancer
Issue Date: 1-Jul-2021
Publisher: Elsevier BV
Abstract: Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by the US Food and Drug Administration. This review examines the role of KRAS mutations in NSCLC and the challenges in targeting KRAS. Based on specific KRAS biology, it reports exciting progress, exploring the use of novel direct KRAS inhibitors as monotherapy or in combination with other targeted therapies, chemotherapy, and immunotherapy.
Note: Reproducció del document publicat a:
It is part of: Lung Cancer, 2021, vol. 160, p. 152-165
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
PIIS0169500221004748.pdf2.54 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons